Crystal Brimer is ready for something different and looks forward to offering new options in her practice. "For me, presbyopia is personal. I’m over 40 now, and I want options. My patients are also looking for that freedom and flexibility to be active without their readers. They're ready for a functional solution that can fit into their daily life. Are you ready for a different solution? Join LENZ at Florida Optometric Association, Jul 18th-21st, in Orlando, FL. www.EyeAmSelective.com #presbyopia #EyeAmSelective
LENZ Therapeutics
Pharmaceutical Manufacturing
San Diego, California 4,897 followers
Focused on innovative science to improve vision
About us
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, California, and is backed by multiple blue-chip venture capital investors.
- Website
-
https://LENZ-Tx.com
External link for LENZ Therapeutics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
Locations
-
Primary
125 S Highway 101
San Diego, California 92075, US
Employees at LENZ Therapeutics
Updates
-
We are hiring! LENZ Therapeutics is searching for a Medical Science Liaison (MSL). This position will serve as a vital link between our company and healthcare professionals, providing scientific and medical support for our product and impactful insights to the company. This role will also be responsible in developing and maintaining relationships with key opinion leaders (KOLs) in the optometry and ophthalmology community. If you are ready to join our team, click link to apply: https://lnkd.in/g-Bh3aak
-
-
LENZ announces a $30M investment from Ridgeback Capital to further strengthen its Balance Sheet with an aim to make LNZ100 a potentially best-in-class therapeutic option for the treatment of presbyopia. “We invest in innovative people and companies that help patients. LENZ is developing a medicine that can have a transformational impact on eyesight. This can benefit millions of people who live with the challenges of presbyopia, and we are excited to support the LENZ team in this effort,” said Dr. Wayne Holman, Chief Executive Officer and Founder of Ridgeback Capital. Read full press release here: https://lnkd.in/gC8B39fJ
-
Sherif El-Harazi, MD looks forward to a solution with a new method of action for presbyopic patients. "We’ve been looking for innovative presbyopia solutions. Up until now, the only options I’ve been able to offer my patients have been invasive and expensive, without giving them true relief. An approach that targets the ideal pupil size is something I’m truly looking forward to." Join LENZ at AECOS (American-European Congress of Ophthalmic Surgery) July 11th-14th in Deer Valley to learn more about why targeting the right muscle is an important consideration for presbyopia solutions. www.EyeAmSelective.com #presbyopia #EyeAmSelective
-
-
Renee Bovelle, MD is confident about recent data in the space, knowing how a small pupil affects depth-of-focus. “As clinicians, it’s important for us to stay in-the-know about emerging treatments. A potential presbyopia solution that targets the ideal pupil size isn't only something that every clinician should be aware of, it’s also something they should be confident about implementing into their practice.” www.EyeAmSelective.com #EyeAmSelective #Presbyopia
-
-
Following its public debut in March, LENZ Therapeutics is excited to now be part of the #Russell2000Index, which is one of the most widely used benchmarks for small-cap stocks. INDEXRUSSELL: LENZ Learn more here: https://lnkd.in/g7PDi3rP
-
Mile Brujic is encouraged by the data of emerging presbyopia solutions, knowing that the details matter for presbyopic patients. “Details matter when it comes to vision. Extending depth of focus through reducing pupil size makes me optimistic for my presbyopic patients.” Are you following the latest research? Visit us at www.EyeAmSelective.com to learn more. #EyeAmSelective #Presbyopia
-
-
LENZ Therapeutics was thrilled with the excitement at our capacity capped Key Opinion Leader (KOL) medical meeting in Nashville last night. Thank you to the panel of investigators, Marc Bloomenstein,O.D., Milton Hom, O.D., Natasha Hindman, O.D., from our Phase 3 CLARITY trial who shared their perspectives on Aceclidine, S. Barry Eiden for moderating the panel and the 100+ ECPs who joined us at the event overlooking Nashville downtown. Make sure to stop by Booth #1103 at the American Optometric Association convention today to learn more about the future of presbyopia solutions. #Presbyopia
-
-
The American Optometric Association meeting begins in just a few minutes. Make sure to stop by booth #1103 to visit the LENZ Therapeutics team and learn more about the future of presbyopia solutions or visit EyeAmSelective.com #AOA #Presbyopia #EyeAmSelective
-
LENZ Therapeutics was excited to host our Key Opinion Leader Event in NY! At the event we presented our Capstone CLARITY data and Principal Investigators Dr. Jason Bacharach, M.D., Dr. Marc Bloomenstein and O.D., Dr. Milton Hom, O.D. shared their real-world perspectives on LNZ100 from the Phase 3 study. Watch the webcast replay here: https://lnkd.in/eFCQZmiQ Downloaded the presentation here: https://lnkd.in/eQeaZN4w
-